Molecular pharmacognosy: an explanatory model

Jan G. Bruhn and Lars Bohlin

Increased interest in the study of natural products as potential drugs and rapidly changing research strategies are driving us to reassess the role of pharmacognosy in the wider context of pharmaceutical research. The authors propose a new definition and an explanatory model of modern pharmacognosy that can be used as a theoretical foundation for future development of this classical branch of the life sciences.

In the latest edition (1996) of the classical textbook *Trease and Evans' Pharmacognosy*[1], pharmacognosy is defined as 'the study of those natural substances, principally plants, that find use in medicine'. In the 1992 edition of *Drugs of Natural Origin* by Gunnar Samuelsson[2], we learn that pharmacognosy deals with 'natural products used as drugs or for the preparation of drugs'. Samuelsson also describes pharmacognosy as a multidisciplinary subject that comprises parts of botany, organic chemistry, biochemistry and pharmacology.

With increasing specialization throughout the pharmaceutical sciences, such broad descriptions, however true, are not specific enough to convey an understanding of the principles underlying modern research and teaching in pharmacognosy. We would like to present here our view of modern pharmacognosy and a model that we have successfully used to explain the subject to scientists of other disciplines, as well as undergraduates in pharmacy and medicine. In addition, we would like to emphasize the continuing usefulness of the pharmacognostic approach in the drug discovery process.

Research in pharmacognosy

The appearance of biologically active metabolites in nature is determined by ecological needs and biosynthetic possibilities. The co-evolution of plants, insects, micro-organisms and mammals leads to the synthesis of secondary metabolites with defensive, attractive and other functions[3].

Classical pharmacognosy dealt with the taxonomy and morphology of plant drugs and neglected their chemistry. In the past 40 years, however, much research has focused on the isolation and structure elucidation of active constituents, but the bioactivity itself has often been neglected. Modern pharmacognosy cannot ignore this fundamental feature of plant-derived drugs, especially because the development of new technologies offers novel research possibilities.

By focusing on biological activity, modern pharmacognostic research has a very good chance of finding new drug leads. In his recent book on drug prototypes, W. Sneader enumerates 244 prototype molecules, most of which are derived from natural products. He also shows that academic research has been a great source of such discoveries[4]. Pharmacognostic research can point the way to new discoveries not only by identifying new structures, but also by pointing to 'new' biological activities. A classical example here is the extensive research on hallucinogenic plant drugs, including the discovery of agents such as mescaline, psilocybin and tetrahydrocannabinol, which has had a profound impact on neuropharmacology. Another brilliant example is the work on poisonous frogs and their toxins (batrachotoxin, epibatidin and histrionicotoxin)[5]. An excellent review on natural products as leads for new pharmaceuticals has recently been published[6].

Jan G. Bruhn and **Lars Bohlin**, Division of Pharmacognosy, Department of Pharmacy, Biomedical Centre, Uppsala University, Box 579, S-751 23 Uppsala, Sweden. tel: +46 18 17 44 92, fax: +46 18 50 91 01, e-mail: Lars.Bohlin@Pharmacog.uu.se

Three-point model

Our model to explain modern pharmacognosy is presented in Figure 1. An organism displaying some kind of biological activity is selected and studied to find a molecular explanation of the activity. Usually, bioassay-directed separation from the complex biomass is undertaken in order to isolate and identify the active constituent(s). This can result in the isolation of both novel and known chemical structures with specific bioactivity (see below). This basic knowledge can then be applied in the drug discovery process for development of new drugs, models for synthesis, precursors for semisynthesis and pharmacological tools.

This model has helped us to look upon our discipline with new eyes. The task of explaining modern pharmacognosy is made a lot easier, and the role of pharmacognosy among the other pharmaceutical sciences is made more clear.

Activity and structure

The search for the bioactive compounds of a specific organism can result in any one of four different possibilities, some of which are more rewarding than others (Figure 2).

1: Known activity/known structure. Too often, considerable effort is expended in the isolation of previously established chemical structures with known bioactivity; for

Figure 1. *Explanatory model for molecular pharmacognosy.*

Figure 2. *Relationship between chemical structure and biological activity.*

example, ubiquitous plant phenolics showing antimicrobial activity. The extract of *Ipomoea pes-caprae* used in Thailand as an antidote against skin damages caused by jelly fish toxins exhibited significant anti-inflammatory activity in experimental models. Bioassay-guided fractionation led to the isolation of eugenol, a known anti-inflammatory compound[7]. However, such results are important for an understanding of the activity of a specific traditional medicine and are necessary in order to be able to standardize drugs to be used in phytotherapy. As lead structures in modern drug discovery, however, such results are of minimal interest.

2: Known activity/new structure. The isolation of new chemical structures but with known activity is typical of modern research in pursuit of a specific biological activity. This can be demonstrated with the isolation of new triterpene saponins with muscle-relaxant activity, called zizyphoisides, from *Alphitonia zizyphoides*[8]. Many compounds are reported as new but are in fact modifications of already known skeletons, exemplified by our isolation of new anti-inflammatory biflavonoids from *Sarcophyte pirei*[9]. In the search for new members of known mechanistic classes, for example finding a novel ligand to a certain receptor, single-specific assays can be used. However, this approach can hardly be expected to reveal entirely new targets for drug action or new mechanisms of action.

3: New activity/known structure. A third possibility, of greater interest, would be to find a new activity coupled to a known structure. Disappointing as this may seem from the purely chemical point of view, it is a most interesting lead, and many related structures are usually already known and can be tested. Such research has long been pursued in the drug industry, where most companies routinely run all available substances through new test systems. In our laboratory, a known plant constituent, a sulfoquinovosyl diacylglycerol (SQDG), was isolated from the fern *Polypodium decumanum* – used in psoriasis. The compound inhibited the exocytosis induced by platelet activating factor (PAF) in human neutrophils *in vitro*[10]. Further *in vitro* studies demonstrated that SQDG causes dose-dependent displacement of [3H]PAF from its receptor. This finding was quite unexpected, but shows the strength of the bioactivity-guided isolation procedure. Such findings direct attention to substance classes that may have been pharmacologically overlooked because they are widely considered to have been fully characterized.

4: New activity/new structure. The final, and most challenging, question is whether we can detect novel substances with novel mechanisms of action. If we adhere to the already established bioassays, the answer will in most cases be 'no'. The assays have been established to detect already known activities. In such circumstances, the prospects of finding new structures as models for future drugs, or as competitors or successors of existing drugs, are limited. In classical pharmacology and pharmacognosy, the effects of drugs were studied in whole animals and in human experiments. These models, however basic, were able to detect new activities. During pharmacological screening in mice of the African *Strychnos* species, one extract induced neurological effects such as abduction of hind legs, tail erection and slight tremor of the head, in addition to its muscle-relaxant effect. This combination of effects was surprising and previously unknown. A new alkaloid, strychnocarpine, was isolated and found to stimulate 5-HT receptors, thus resembling LSD in action[11].

A careful analysis of the pharmacological pattern of natural product mixtures undergoing high-throughput screening will probably also identify new pharmacological profiles and eventually lead to novel structures.

Further research can of course uncover completely new mechanisms of activity that are not revealed in the first screening. This can be exemplified with the discovery of camptothecin with a novel structure but with the known antitumour activity to prolong life of mice treated with L1210 leukaemia cells. Further research showed that camptothecin, by a unique mechanism, inhibits the enzyme topoisomerase I (Ref. 12). A further discussion of bioassay methods used in natural product research aimed at drug lead discovery is presented elsewhere[13].

Role of academic research

The objective for natural product research aimed at drug lead discovery is to find unique chemical structures with a new mode of action. This is a very challenging area for academic research, but also one of new possibilities. For the drug industry, it is most important to generate leads efficiently – rapidly and cheaply, and on the basis of a high degree of chemical diversity. It is obvious that academic research cannot proceed in this way, even if the goal is the same[14].

Academic research in the field of natural products should therefore focus on defining scientific problems for which the solution will yield fundamentally new data and insights. Our goal is to establish successful strategies in the search for specific, potentially useful natural products with biological or other activities and, preferably, novel structures.

We have therefore reorganized our own research, on the basis of the proposed model, into two major projects: 'natural products with anti-inflammatory activity' and 'biologically active peptides of plant origin'. The focal point in the first project is the *biological activity*, and in the second the *chemical structure*. Important aspects of this research include the following:

- development of fractionation protocols and separation methods that permit isolation of minute quantities of bioactive substances from plant biomass with complex chemical composition;
- development of selection strategies for plant materials based on biodiversity, ethnomedicine and chemotaxonomy;
- structure determination of isolated substances; and
- characterization of biological (pharmacological) properties of isolated substances on organ (guinea pig ileum), cell (human neutrophil) and enzyme (COX-1, COX-2, elastase and neuropeptidases) levels.

Research activities are also focused on how to dereplicate – how to avoid the repetitive isolation of common and well known structures with known biological activity and how to

prevent the emergence of artefacts and interference with the bioassay applied. Other groups are formulating similar research strategies[15].

Molecular pharmacognosy

Our didactic model illustrates that pharmacognosy is now a molecular science (cf. Ref. 16). Therefore, we propose the following definition based on the above:

> Pharmacognosy is a molecular science that explores natu-
> rally occurring structure–activity relationships with a drug
> potential.

Pharmacognosy has generally been pursued for utilitarian ends, and this is reflected in the increased interest in herbal drugs and in natural product-based drug discovery in the industry[17,18]. This is augmented by the interest in the application of natural products as pharmacological tools, synthones and models in the drug development process. In our model, these two major applications form two branches of applied research (see Figure 1).

As pointed out by G.M. Cragg and others, no chemist could ever dream up a structure like paclitaxel. Learning from the paclitaxel story, the National Cancer Institute (Bethesda, MD, USA) and other research organizations now sense the necessity to develop new screens and to look upon nature as the largest and most diverse combinatorial library available[19].

The ability of modern pharmacognosists (a) to select organisms *and* activities of potential interest, and (b) to avoid the pitfalls of re-isolating substances already well known pharmacologically, will determine the success or failure of the present interest in drug discovery from natural sources.

REFERENCES

1 Evans, W.C. (1996) *Trease and Evans' Pharmacognosy* (14th edn), W.B. Saunders
2 Samuelsson, G. (1992) *Drugs of Natural Origin* (3rd edn), Swedish Pharmaceutical Press
3 Rhodes, M.J.C. (1994) *Plant Mol. Biol.* 24, 1–20
4 Sneader, W. (1996) *Drug Prototypes and their Exploitation*, John Wiley & Sons
5 Daly, J.W., Garraffo, M. and Spande, T.F. (1993) in *The Alkaloids, Chemistry and Pharmacology* (Vol. 43) (Cordell, G.A., ed.), pp. 185–288, Academic Press
6 Buss, A.D. and Waigh, R.D. (1995) in *Burger's Medicinal Chemistry and Drug Discovery* (Vol. 1, 5th edn) (Wolff, M.E., ed.), pp. 983–1033, John Wiley & Sons
7 Pongprayoon, P. *et al.* (1991) *Planta Med.* 57, 515–518
8 Perera, P. *et al.* (1993) *Magn. Res. Chem.* 31, 472–480
9 Ogundaini, A. *et al.* (1996) *J. Nat. Prod.* 59, 587–590
10 Vasänge, M., Rolfsen, W. and Bohlin, L. (1997) *J. Pharm. Pharmacol.* 49, 562–566
11 Rolfsen, W., PhD Thesis, Uppsala University, 1980
12 Wall, M.E. and Wani, M.C. (1996) *J. Ethnopharmacol.* 51, 239–254
13 Claeson, P. and Bohlin, L. *Trends Biotechnol.* (in press)
14 Cordell, G.A. (1995) *Phytochemistry* 40, 1585–1612
15 Williamson, E.M., Okpako, D.T. and Evans, F.J. (1996) *Pharmacological Methods in Phytotherapy Research: Selection, Preparation and Pharmacological Evaluation of Plant Material* (Vol. 1), John Wiley & Sons
16 Bohlin, L. (1993) *J. Ethnopharmacol.* 38, 225–231
17 Editorial (1994) *Lancet* 343, 1513–1515
18 Press, J.B. (1996) *Chemtracts-Organic Chemistry* 9, 286–298
19 Cragg, G.M., Newman, D.J. and Snader, K.M. (1997) *J. Nat. Prod.* 60, 52–60

In the July issue of *Drug Discovery Today*...

Update – latest news and views

The therapeutic potential of TNF-α inhibitors old and new – J. Blake Marriott, Michael Westby and Angus G. Dalgleish

CCK$_B$/gastrin receptor antagonists as potential drugs for peptic ulcer therapy – Francesco Makovec and Massimo D'Amato

Serotonin receptors as cardiovascular targets – Carlos M. Villalón, Peter de Vries and Pramod R. Saxena

Clinically effective HIV-1 protease inhibitors – Jon H. Condra and Joseph P. Vacca

Monitor – new bioactive molecules, high-throughput screening, combinatorial chemistry, emerging molecular targets